ArticleJournal of clinical microbiology2002
In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 70 citations in OpenAlex.
- Modulators of Candida albicans Membrane Drug Transporters: A Lucrative Portfolio for the Development of Effective Antifungals.Molecular biotechnology · 2024Review
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- [Purpureocillium lilacinum : Atypical pathogen of mycotic keratitis in an immunocompetent patient].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Article
- Article
- In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs onJournal of fungi (Basel, Switzerland) · 2021Article
- Strategies to Better Target Fungal Squalene Monooxygenase.Journal of fungi (Basel, Switzerland) · 2021Review
- Synergistic Interactions of Schizostatin Identified fromThe plant pathology journal · 2020Article
- Structural design of microbicidal cationic oligomers and their synergistic interaction with azoles against Candida albicans.Scientific reports · 2019Article
- Review
- Combination Antifungal Therapy: A Review of Current Data.Journal of clinical medicine research · 2017Review
- Review
- Posaconazole: An Update of Its Clinical Use.Pharmacy (Basel, Switzerland) · 2015Review
- Clinical, morphological, and molecular characterization of Penicillium canis sp. nov., isolated from a dog with osteomyelitis.Journal of clinical microbiology · 2014Article
- Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.Antimicrobial agents and chemotherapy · 2011Article
- Antifungal suscepitibility profile of candida spp. oral isolates obtained from denture wearers.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2008Article
- Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.Antimicrobial agents and chemotherapy · 2005Article
- Combination treatment of invasive fungal infections.Clinical microbiology reviews · 2005Review
- In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.Antimicrobial agents and chemotherapy · 2004Article
- Combination antifungal therapy.Antimicrobial agents and chemotherapy · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A checkerboard microdilution method, performed according to the recommendations of the National Committee for Clinical Laboratory Standards, was used to study the in vitro interaction of terbinafine (TRB) with fluconazole (FLU), itraconazole (ITRA), voriconazole (VRC), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles isolated from the oral cavities of human immunodeficiency virus patients. Synergy, defined as a fractional inhibitory concentration index of < or =0.5, was observed in 17% of TRB-FLU interactions, 21% of TRB-ITRA interactions, 33% of TRB-VRC interactions, and 12% of TRB-PSZ interactions. Where synergy was not achieved, there was still a decrease in the MIC of one or both drugs when used in combination. Antagonism was not observed in any drug combination. Clinical studies are warranted to elucidate the potential utility of these combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.